
Reza Ghasemi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10600645/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia, 2021, 35, 404-416.	7.2	20
2	Homozygous Loss of a Critical CTCF Recognition Sequence in the HOXA gene Cluster Eliminates CTCF Binding but Does Not Appreciably Reduce HOXA9 expression in NPM1 Mutated AML Cells. Blood, 2018, 132, 2613-2613.	1.4	0
3	Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncolmmunology, 2017, 6, e1265721.	4.6	7
4	Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Scientific Reports, 2017, 7, 4204.	3.3	27
5	Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance. Oncolmmunology, 2016, 5, e1238543.	4.6	8
6	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nature Communications, 2016, 7, 12878.	12.8	51
7	Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. Tumor Biology, 2016, 37, 3913-3923.	1.8	13
8	Multitargeting and Antimetastatic Potentials of Silibinin in Human HepG-2 and PLC/PRF/5 Hepatoma Cells. Nutrition and Cancer, 2013, 65, 590-599.	2.0	25
9	Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anti-Cancer Drugs, 2010, 21, 252-260.	1.4	35